Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
|Articles|June 15, 2016
- BioPharm International-06-15-2016
- Volume 2016 ebook
- Issue 1
Dealing with Pharmaceutical Supply-Chain Complexities
Author(s)Michael Schmitz
Planning ahead is key to enabling a continuous and secure supply chain that adapts to changes in market demand.
Advertisement
The pharmaceutical supply chain faces many changes, and service providers have to accept changes in market demand and adapt to the circumstances accordingly. Experienced contract
development and manufacturing organizations (CDMOs) can offer answers to the challenging supply chain and deliver high product quality.
Articles in this issue
over 10 years ago
Contract Service Providers Gear Up to Develop Emerging Therapiesover 10 years ago
Biopharma Service Providers Address a Full Plate of Challengesover 10 years ago
Keeping it Simple: Collaborating for Success in Drug Deliveryover 10 years ago
Biomanufacturers Demand Higher Quality Standards in 2016over 10 years ago
Preventing Phase III Failuresover 10 years ago
Outsourcing Industry Marked by Considerable Investments in 2016Advertisement
Related to this article
ADC trials are moving from binary antigen testing to quantitative, multiparameter biomarker models that better predict efficacy and toxicity.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
Advertisement
Advertisement
Trending on BioPharm International
1
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
2
T-Therapeutics Raises $133 Million to Take TCR Bispecifics Into the Clinic
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
5